289902-88-1

Basic information

• Product Name: 2-(3,4-dimethylbenzyl)propane-1,3-diol
• Synonyms: 2-(3,4-dimethylbenzyl)propane-1,3-diol;2-(3,4-diMethylbenzyl)-1,3-propanediol
• CAS NO: 289902-88-1
• Molecular Formula: C₁₂H₁₈O₂
• Molecular Weight: 194.272
• Mol File: 289902-88-1.mol

Chemical Properties

• Boiling Point: 362.2°C at 760 mmHg
• Flash Point: 174.6°C
• Appearance: /
• Density: 1.06g/cm³
• Vapor Pressure: 7.04E-06mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: 2-(3,4-dimethylbenzyl)propane-1,3-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-dimethylbenzyl)propane-1,3-diol(289902-88-1)
• EPA Substance Registry System: 2-(3,4-dimethylbenzyl)propane-1,3-diol(289902-88-1)

Safety Data

• Hazardous Substances Data: 289902-88-1(Hazardous Substances Data)

Usage

Diol

Two hydroxyl (OH) functional groups This compound has two hydroxyl groups, which contribute to its solubility and reactivity.

Fragrance ingredient

Commonly used in personal care and cosmetic products 2-(3,4-dimethylbenzyl)propane-1,3-diol is a popular component in various fragrances due to its pleasant, floral scent.

Sweet, fruity aroma

Adds a desirable scent to perfumes, lotions, and soaps The compound is often used to enhance the aroma of personal care products, giving them a sweet and fruity fragrance.

Antimicrobial properties

Useful as a preservative in skincare products The compound's ability to inhibit the growth of microorganisms makes it an effective preservative in beauty and personal care products, helping to prevent spoilage and maintain product quality.

Valued for fragrance and preservation abilities

Important in the beauty and personal care industry The combination of its pleasant scent and antimicrobial properties make 2-(3,4-dimethylbenzyl)propane-1,3-diol a valuable compound in the formulation of various personal care products.

InChI:InChI=1/C12H18O2/c1-9-3-4-11(5-10(9)2)6-12(7-13)8-14/h3-5,12-14H,6-8H2,1-2H3

Upstream product

• 289902-87-0 diethyl 3,4-dimethylbenzylmalonate 
• 102-46-5 4-(chloromethyl)-1,2-dimethylbenzene 

Downstream Products

• 289902-89-2 2-(3,4-dimethylbenzyl)-3-hydroxypropyl acetate 
• 289902-97-2 2-(3,4-dimethylbenzyl)-3-hydroxypropyl azide 
• 289902-93-8 3-azido-2-(3,4-dimethylbenzyl)propyl acetate 
• 401573-58-8 N-[2-(3,4-dimethylbenzyl)-3-pivaloyloxy-propyl]hydroxylamine 
• 289903-12-4 3-azido-2-(3,4-dimethylbenzyl)propyl pivalate 
• 289903-14-6 3-azido-2-(3,4-dimethylbenzyl)propyl benzoate 
• 289903-16-8 3-azido-2-(3,4-dimethylbenzyl)propyl 3,4-dimethylbenzoate 
• 1025985-78-7 2,2-dimethyl-propionic acid 2-(3,4-dimethyl-benzyl)-3-[3-(3-methoxy-4-methoxymethoxy-benzyl)-thioureido]-propyl ester 

Relevant articles and documents

Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof

The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for treating acute, chronic, inflammatory or neuropathic pains or for treating bladder hypersensitivity.

N-(3-acyloxy-2-benzylpropyl)-N′-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics

A series of N-(3-acyloxy-2-benzylpropyl)-N′-(4-hydroxy-3-methoxybenzyl)thiourea derivatives were investigated as vanilloid receptor ligands in an effort to discover a novel class of analgesics. The proposed pharmacophore model of resiniferatoxin, which includes the C20-homovanillic moiety, the C3-carbonyl and the orthoester phenyl ring as key pharmacophoric groups, was utilized as a guide for drug design. The compounds were synthesized after several steps from diethylmalonate and evaluated in vitro in a receptor binding assay and in a capsaicin-activated channel assay. Additional evaluation of analgesic activity, anti-inflammatory activity and pungency was conducted in animal models by the writhing test, the ear edema assay, and the eye-wiping test, respectively. Among the new compounds, 23 and 28 were found to be the most potent receptor agonists of the series with Ki values of 19 nM and 11 nM, respectively. Their strong in vitro potencies were also reflected by an excellent analgesic profile in animal tests with ED50 values of 0.5 μg/kg for 23 and 1.0 μg/kg for 28. Relative to capsaicin these compounds appear to be ca. 600 and 300 times more potent. Both 23 and 28 were found to be less pungent than capsaicin based on the eye-wiping test. However, the compounds did not show significant anti-inflammatory activity. A molecular modeling study comparing the energy-minimized structures of resiniferatoxin and 35 demonstrated a good correlation in the spatial disposition of the corresponding key pharmacophores. The thioureas described in this investigation, which were designed as simplified resiniferatoxin surrogates, represent a novel class of potent vanilloid receptor agonists endowed with potent analgesic activity and reduced pungency.